Satoru Watanabe

Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial

Jenny G. Low, Cynthia Sung, Limin Wijaya et al. · The Lancet Infectious Diseases · 2014 · 240 citations

Phase 1B, Proof-of-concept Trial, Clinical Trials +5

Hematopoietic stem cell–engrafted NOD/SCID/IL2Rγnull mice develop human lymphoid systems and induce long-lasting HIV-1 infection with specific humoral immune responses

Satoru Watanabe, Kazuo Terashima, Shinrai Ohta et al. · Blood · 2006 · 200 citations · Full text

A New Humanized Mouse Model of Epstein‐Barr Virus Infection That Reproduces Persistent Infection, Lymphoproliferative Disorder, and Cell‐Mediated and Humoral Immune Responses

Misako Yajima, Ken‐Ichi Imadome, Atsuko Nakagawa et al. · The Journal of Infectious Diseases · 2008 · 179 citations

Humoral Immune Responses, Humoral Response, Immune Regulation +19

Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse model

Abhay P. S. Rathore, Prasad N. Paradkar, Satoru Watanabe et al. · Antiviral Research · 2011 · 158 citations

Celgosivir Treatment Misfolds, Medicine, Pathogenesis +8

Luteolin restricts dengue virus replication through inhibition of the proprotein convertase furin

Minhua Peng, Satoru Watanabe, Kitti Wing Ki Chan et al. · Antiviral Research · 2017 · 130 citations · Full text

Dengue Virus Replication, Viral Replication, Molecular Virology +6